Welcome to our dedicated page for Prothena SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prothena Corporation plc (NASDAQ: PRTA) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, alongside AI-powered summaries designed to make these documents easier to understand. Prothena is an Irish public limited company whose ordinary shares trade on The Nasdaq Global Select Market, and it files reports such as Forms 8-K and proxy statements in connection with material events and shareholder meetings.
Recent 8-K filings referenced by the company include disclosures about quarterly financial results, workforce reductions following the discontinuation of the birtamimab program, collaboration developments such as Novo Nordisk advancing coramitug (formerly PRX004) for ATTR amyloidosis with cardiomyopathy, and updates on the PRX012 Phase 1 ASCENT clinical program. Other 8-Ks describe governance and compensation matters, including employment agreements for senior officers and the planned resignation of a Board member, as well as the outcome of an Extraordinary General Meeting where shareholders approved a reduction of capital to create distributable reserves.
Prothena’s definitive proxy statement for the Extraordinary General Meeting explains the rationale for the capital reduction and outlines voting procedures for shareholders of the Irish public limited company. These filings, together with the company’s periodic reports referenced in its press releases, form the official record of Prothena’s financial condition, capital structure decisions, and key operational events.
On Stock Titan, users can access Prothena’s SEC filings as they are made available through EDGAR and use AI-generated highlights to quickly identify the main points in lengthy documents. For PRTA, this can include understanding how collaboration revenue from partners like Bristol Myers Squibb is reported, how restructuring charges are described, and how shareholder approvals are documented in connection with potential share redemption programs and other capital management actions.
On 28 Jul 2025, Prothena Corporation plc (PRTA) filed a Form 4 reporting that its Chief Scientific Officer, Dr. Wagner M. Zago, acquired 85,000 ordinary shares of the company. The transaction was coded “A,” indicating an acquisition that was not purchased for cash (reported price $0), consistent with an equity award or similar grant. Following the transaction, Dr. Zago’s direct beneficial ownership totals 85,000 shares. No derivative securities were reported, and there were no dispositions. The filing was signed by Michael J. Malecek under power of attorney on 30 Jul 2025.